Shots:
- BD to combine its Biosciences & Diagnostic Solutions business with Waters in a Reverse Morris Trust transaction
- As per the deal, BD shareholders will receive $4B in cash & a 39.2% stake in the combined company, while Waters will assume $4B in debt & retain 60.8%, with the total deal value of $17.5B reflecting cash, assumed debt, & BD’s equity stake; Combined entity will be listed on NYSE under ticker ‘WAT’ following closing in Q1’26
- Merger will combine Waters’ strengths in chemistry, informatics, & QA/QC with BD’s capabilities in biologics, flow cytometry, & molecular diagnostics to drive innovation in bio separations, large molecule analytics, & multiplex diagnostics as well as expand market access
Ref: PRNewswire | Image: Becton & Dickinson & Company| Press Release
Related News:- Ascentage Pharma Reports the NMPA’s Conditional Approval of Lisaftoclax for the Treatment of CLL/SLL
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
